CROMA POLYPHIL™ NEXT
Name: CROMA POLYPHIL™ NEXT
Manufacturer: Croma
Active Substance(s): PN-HPT®, HYALURONIC ACID
Strength: 20mg, 20mg
Package Content: 1 x 2ml Pre-Filled Syringes
In Stock
CROMA POLYPHIL™ NEXT is Croma-Pharma’s dual-molecule injectable combining 20 mg/2ml PN-HPT® polynucleotide with 20 mg/2ml non-crosslinked hyaluronic acid (10 mg/ml each) in a single pre-filled syringe. It’s formulated for deeper tissue targets, including deep wrinkles, atrophic scars, and stretch marks (striae distensae), and is sold internationally as PhilArt NEXT.
Specifications
Description
Name: CROMA POLYPHIL™ NEXT
Manufacturer: Croma
Active Substance(s): PN-HPT®, HYALURONIC ACID
Strength: 20mg, 20mg
Package Content: 1 x 2ml Pre-Filled Syringes
CROMA POLYPHIL™ NEXT 20mg Injection — PN-HPT® + Hyaluronic Acid Hybrid for Deep Wrinkles, Scars & Stretch Marks
Formulated for deeper tissue targets than a PN-only booster reaches, CROMA POLYPHIL™ NEXT is Croma-Pharma’s dual-molecule syringe combining 20 mg/2ml PN-HPT® polynucleotide (10 mg/ml) with 20 mg/2ml non-crosslinked hyaluronic acid (10 mg/ml). The same product is sold internationally as PhilArt NEXT and addresses deep wrinkles, atrophic scars, and stretch marks across the face, neck, décolletage, and body zones. Practitioners and consumers looking to buy CROMA POLYPHIL™ NEXT for scar or stretch-mark protocols can order it through Direct Doctor Supply, a trusted supplier since 2014.
Product Specifications
- Strength: 20 mg/2ml PN-HPT® polynucleotide (10 mg/ml) plus 20 mg/2ml non-crosslinked hyaluronic acid (10 mg/ml) per pre-filled syringe
- Active ingredients: PN-HPT® highly purified long-chain sodium polynucleotides, extracted from salmonidae (salmon and trout) sperm DNA. Screen carefully for documented severe fish or seafood allergy before treatment. Second active: non-crosslinked hyaluronic acid
- Dosage form: injectable gel; 1 x 2ml pre-filled syringe with sterile needles per package specification (30G supplied; gauge adjusted per depth and indication)
- Manufacturer: Croma-Pharma GmbH, Austria
- Brand: CROMA POLYPHIL™ NEXT (also marketed internationally as PhilArt NEXT)
- Country of origin: Austria
- Regulatory status: CE-marked Class III aesthetic injectable medical device (EU) [1]. Not FDA-cleared or approved for aesthetic use in the United States. MHRA (UK), TGA (Australia), and Health Canada availability varies and should be verified at the time of order
- Intended use: delivered intradermally (deep reticular dermis) or at the dermal-subcutaneous junction depending on target depth and indication, for deeper tissue applications including deep wrinkles, atrophic scars, and stretch marks (striae distensae). True subcutaneous fat placement is generally avoided, since it would sit beneath the target fibroblast population
- Storage: store between 2 and 25°C; do not freeze; protect from light
What Makes the CROMA POLYPHIL™ NEXT PN HA Hybrid Different?
CROMA POLYPHIL™ NEXT is the only member built around a dual active. The PN-HPT® component provides the biostimulatory signal common to the whole POLYPHIL™ family. The non-crosslinked HA layered onto it delivers immediate hydration at the injection site and forms a temporary matrix that keeps polynucleotide fragments in a workable microenvironment while dermal remodeling gets underway.
That difference matters clinically. The flagship 40mg/2ml PN-only syringe is aimed at general biorevitalization of skin quality. NEXT targets deeper tissues where a working scaffold materially helps remodeling, such as atrophic scar tissue, mature striae, and deep wrinkles. The HA element is metabolized by hyaluronidase over weeks and does not leave behind structural volume the way a cross-linked HA filler would.
CROMA POLYPHIL™ NEXT and PhilArt NEXT are two trade names for the same syringe, sold under different labels in different markets. Clinicians expanding into scar or body-zone work often buy polynucleotides across the category before deciding whether the PN-only or PN plus HA route fits the case.
Indications & Treatment Areas
CROMA POLYPHIL™ NEXT is positioned for a broader and deeper indication set than PN-only biorevitalization. Reported use cases include:
- Deep wrinkles and folds not adequately reached by superficial biorevitalization
- Atrophic acne scars and post-traumatic scars
- Stretch marks (striae distensae), both early and mature
- Skin quality improvement in body zones affected by dermal thinning
- Adjunctive use alongside cross-linked HA fillers or resurfacing procedures, at the practitioner’s discretion
CROMA POLYPHIL™ NEXT for deep wrinkles, for scars, and for stretch marks are the three most common search queries, and they map to the indication set above. Per the Croma-Pharma IFU, treatment areas include the face, neck, décolletage, and body zones such as inner arms, abdomen, and thighs. Clinics running body-treatment programs regularly buy CROMA POLYPHIL™ NEXT wholesale to keep per-syringe cost stable across a course of scar or striae sessions. Practitioners combining polynucleotide work with volumetric contour restoration also tend to buy dermal fillers from the same distributor to consolidate ordering.
CROMA POLYPHIL™ NEXT Mechanism of Action
Delivered into the deep reticular dermis, or at the dermal-subcutaneous junction where scar or striae anatomy calls for it, the PN-HPT® component of CROMA POLYPHIL™ NEXT acts as a temporary scaffold and as the substrate that endogenous enzymes gradually break down into shorter nucleoside and nucleotide fragments. Those fragments engage adenosine receptors on fibroblasts. A2A activation is the primary pathway cited for fibroblast stimulation and the upregulation of type I collagen and elastin synthesis, with A2B and other purinergic subtypes also engaged [2].
Several complementary routes contribute simultaneously. The polynucleotide chain acts as an antioxidant buffer against reactive oxygen species accumulating in scarred, sun-damaged, or aging tissue, and the released fragments feed the nucleotide salvage pathway, where resident cells reuse them for endogenous DNA repair [3]. The anti-inflammatory activity documented for PN-HPT® supports remodeling in tissue with a low-grade inflammatory component.
The non-crosslinked HA does something different. It hydrates immediately at the injection site and creates a workable matrix in the surrounding tissue during the weeks the PN-HPT® is remodeling. Hyaluronidase then metabolizes it, so it does not remain as structural volume. This is the material distinction from cross-linked HA fillers: the HA in NEXT supports the biostimulation phase rather than replacing it.
CROMA POLYPHIL™ NEXT Treatment Protocol & Administration
CROMA POLYPHIL™ NEXT protocols follow the current Croma-Pharma IFU and typically differ by indication. Scar and striae courses generally involve multiple sessions, with intervals and injection depth (deep intradermal, dermal-subcutaneous junction, or subcision-adjacent for fibrotic tissue) determined by treatment area, tissue response, and practitioner assessment. Practitioners should verify current session count and volume guidance against the Croma-Pharma IFU before finalizing a plan [1].
Common injection technique options include:
- Retrograde linear placement for broader coverage across a treatment area
- Subcision-adjacent technique around tethered or fibrotic scar tissue
- Nappage or microdroplet for more superficial intradermal delivery.
The package supplies 30G needles. Select gauge and injection depth based on the indication and treatment area. Store the syringe at 2 to 25°C, protect from light, do not freeze, and maintain standard aseptic technique. Administration is for qualified injectors only.
Patients should avoid sun exposure, saunas, and strenuous exercise for 24 to 48 hours after treatment. Mild swelling or bruising is expected, particularly when treating body areas.
CROMA POLYPHIL™ NEXT Benefits & Expected Results Timeline
Immediately after treatment, most patients notice hydration and skin surface improvement driven primarily by the HA component. From the second session onward, more measurable changes in dermal quality and the appearance of scars or stretch marks appear as polynucleotide-driven remodeling builds [1].
General improvements are typically maintained for six to twelve months. Scar and stretch mark outcomes often continue to develop longer as the deeper remodeling runs its course. Reported changes commonly include softer scar edges, improved surface texture across striae, and reduced depth of treated wrinkles across a course. Scar and striae improvement is gradual and rarely complete; patients should be counseled to expect appearance improvement rather than elimination.
CROMA POLYPHIL™ NEXT Side Effects & Safety
Reported side effects are usually mild and short-lived, with a safety profile consistent with the wider PN-HPT® line [1][3]. Common effects include
- Mild erythema
- Swelling
- Bruising
- Tenderness at injection points, generally resolving within a few days
Deeper delivery into body zones can produce longer-lasting bruising than superficial injections. Uncommon reactions include small papules or nodules that usually resolve as the product integrates.
Rare but serious risks include vascular events, infection, and hypersensitivity reactions, which warrant prompt clinical attention.
Contraindications include active infection at the injection site and known hypersensitivity to polynucleotides or hyaluronic acid. Because PN-HPT® is extracted from salmon and trout DNA, patients with documented severe fish or seafood allergy should be screened carefully before treatment. Follow the current IFU for pregnancy and lactation, and assess autoimmune conditions on a case-by-case basis.
The CROMA POLYPHIL™ Product Family
CROMA POLYPHIL™ NEXT sits within Croma-Pharma’s broader polynucleotide range. The 40mg/2ml (20 mg/ml) PN-only flagship, CROMA POLYPHIL™, is used for general biorevitalization of face, neck, and body. CROMA POLYPHIL™ EYE is a 15mg/2ml periocular presentation for dark circles, tear troughs, and crow’s feet. CROMA POLYPHIL™ HAIR is a 15mg/2ml scalp presentation for hair-restoration protocols.
Where to Buy CROMA POLYPHIL™ NEXT Online — Direct Doctor Supply
CROMA POLYPHIL™ NEXT is available through Direct Doctor Supply for licensed aesthetic professionals and general consumers researching scar or stretch mark treatments for personal plans. Before you purchase CROMA POLYPHIL™ NEXT online, verify the following:
- LOT number traceability to the manufacturer
- Certificate of authenticity
- Cold-chain integrity from warehouse to delivery
- Reputable, verifiable distributor credentials
Buy CROMA POLYPHIL™ NEXT Wholesale from Direct Doctor Supply
Direct Doctor Supply ships authentic, manufacturer-sourced CROMA POLYPHIL™ NEXT at wholesale pricing with tiered volume discounts, packaged for cold-chain transit and tracked in shipping. Formerly known as Maylips.com, the supplier has served the same buyer base since 2014. Clinics running multi-session scar or striae programs can buy CROMA POLYPHIL™ NEXT wholesale to keep per-syringe cost stable across the course, and individual buyers can add single syringes to the same order.
For ordering questions, wholesale inquiries, bulk procurement across the CROMA POLYPHIL™ family, or shipping updates, message the Direct Doctor Supply support team.
Legal & Regulatory Status
CROMA POLYPHIL™ NEXT is a CE-marked Class III aesthetic injectable medical device manufactured in Austria by Croma-Pharma GmbH. Polynucleotide and PDRN aesthetic injectables are not FDA-cleared or approved for cosmetic use in the United States. Regional availability under the UK MHRA, Australian TGA, and Health Canada frameworks varies and should be verified at the time of order (current as of 2026). Administration is intended for trained injectors. Direct Doctor Supply supplies both licensed practitioners and consumers who arrange administration through a qualified provider.
What is CROMA POLYPHIL™ NEXT used for?
Deeper tissue targets: deep wrinkles, atrophic scars, and stretch marks (striae distensae). Treatment areas per the IFU include face, neck, décolletage, and body zones such as inner arms, abdomen, and thighs.
How does CROMA POLYPHIL™ NEXT work?
PN-HPT® breaks down in the dermis into nucleoside and nucleotide fragments that activate A2A adenosine receptors on fibroblasts, driving collagen and elastin synthesis. Antioxidant scavenging and nucleotide salvage contribute in parallel. The non-crosslinked HA adds immediate hydration and a temporary matrix that supports the remodeling phase.
How many CROMA POLYPHIL™ NEXT sessions are needed?
Scar and stretch mark protocols typically involve multiple sessions spaced two to four weeks apart, with maintenance thereafter. Confirm the current schedule against the Croma-Pharma IFU.
What are the side effects of CROMA POLYPHIL™ NEXT?
Mild redness, swelling, bruising, and tenderness at injection sites, settling within a few days. Deeper body-zone delivery can produce longer-lasting bruising. Serious events are rare; refer to the IFU.
What can I expect from CROMA POLYPHIL™ NEXT before and after treatment?
Reported changes commonly include softer scar edges, improved striae texture, and reduced wrinkle depth over time. Improvement is gradual and rarely complete; individual outcomes vary.
Where can I buy CROMA POLYPHIL™ NEXT online?
Direct Doctor Supply (formerly Maylips.com) has stocked authentic Croma-Pharma CROMA POLYPHIL™ NEXT for licensed practitioners and consumers since 2014, with wholesale pricing and tracked shipping. Reach the Direct Doctor Supply support team for ordering guidance.
All content on this website is intended for informational purposes and does not constitute medical advice.
Citations
[1] Cavallini, Maurizio et al. “Consensus report on the use of PN-HPT™ (polynucleotides highly purified technology) in aesthetic medicine.” Journal of cosmetic dermatology vol. 20,3 (2021): 922-928. doi:10.1111/jocd.13679
[2] Byun, Kyung-A et al. “Polynucleotides Enhance Collagen Synthesis via Modulating Phosphoenolpyruvate Carboxykinase 1 in Senescent Macrophages: Experimental Evidence.” International journal of molecular sciences vol. 26,17 8720. 7 Sep. 2025, doi:10.3390/ijms26178720
[3] Lee, Kar Wai Alvin et al. “Polynucleotides in Aesthetic Medicine: A Review of Current Practices and Perceived Effectiveness.” International journal of molecular sciences vol. 25,15 8224. 27 Jul. 2024, doi:10.3390/ijms25158224
Important Information
Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.
Direct Doctor Supply sources its inventory only through authorized distribution channels, so every order arrives sealed in the manufacturer’s original packaging. Our sourcing standards and tracked delivery mean you receive authentic original products every time.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.






